The global viral and non-viral vector manufacturing market was valued at $1.50 billion in 2020 and is expected to reach $27.03 billion by 2031, witnessing a CAGR of 18.54% during the forecast period 2021-2031.
The global aseptic pharma processing market was valued to be $10,633.3 million in 2020 and is expected to reach $24,364.0 million by 2031, witnessing a CAGR of 7.90% during the forecast period 2021-2031.
Aseptic Pharma Processing Market - Global and Regional AnalysisBIS Research Inc.
The global aseptic pharma processing market was valued to be $10,633.3 million in 2020 and is expected to reach $24,364.0 million by 2031, witnessing a CAGR of 7.90% during the forecast period 2021-2031.
Next Generation Gynecological Cancer Diagnostics Market.pdfBIS Research Inc.
Next-Generation Gynecological Cancer Diagnostics market to grow at a significant CAGR of 10.07% during 2020-2031. Next-Generation Gynecological Cancer Diagnostics market report by BIS Research provides deep market insight, industry analysis, trends & forecast to 2031 that will help your business to grow.
Laboratory Informatics Market Analysis and Forecast, 2022-2032BIS Research Inc.
The global laboratory informatics market is anticipated to reach $12,677.0 million by 2032, witnessing a CAGR of 10.27% during the forecast period 2022-2032.
TOC - Global Extensive Stage Small Cell Lung Cancer Market.pdfBIS Research Inc.
Extensive stage small cell lung cancer is extremely aggressive sub-type of small cell lung cancer. Small cell lung itself is a sub-type of lung cancer which accounts for less than 20% cases. The treatment of extensive stage small cell lung cancer has been extremely challenging owing to poor survival rate of the patients.
The prevalence of extensive stage small lung cancer is estimated to increase in five of the seven major markets included in the study.
Our healthcare experts have found PD-1/PD-L1 immunotherapy to be one of the most rapidly adopted therapies, and the global market for PD-1/PD-L1 immunotherapy is predicted to grow at a CAGR of 10.72% over the forecast period of 2020-2030.
The global biomaterials market was valued at $122.92 billion in 2020 and is expected to reach $725.88 billion by 2031, growing at a CAGR of 17.98% between 2021 and 2031.
The global brain imaging modalities market report highlights that the market was valued at $12,334.2 million in 2021 and is expected to reach $20,209.2 million by the end of 2031. The market is expected to grow at a CAGR of 5.06% during the forecast period 2022-2031.
The global aseptic pharma processing market was valued to be $10,633.3 million in 2020 and is expected to reach $24,364.0 million by 2031, witnessing a CAGR of 7.90% during the forecast period 2021-2031.
Aseptic Pharma Processing Market - Global and Regional AnalysisBIS Research Inc.
The global aseptic pharma processing market was valued to be $10,633.3 million in 2020 and is expected to reach $24,364.0 million by 2031, witnessing a CAGR of 7.90% during the forecast period 2021-2031.
Next Generation Gynecological Cancer Diagnostics Market.pdfBIS Research Inc.
Next-Generation Gynecological Cancer Diagnostics market to grow at a significant CAGR of 10.07% during 2020-2031. Next-Generation Gynecological Cancer Diagnostics market report by BIS Research provides deep market insight, industry analysis, trends & forecast to 2031 that will help your business to grow.
Laboratory Informatics Market Analysis and Forecast, 2022-2032BIS Research Inc.
The global laboratory informatics market is anticipated to reach $12,677.0 million by 2032, witnessing a CAGR of 10.27% during the forecast period 2022-2032.
TOC - Global Extensive Stage Small Cell Lung Cancer Market.pdfBIS Research Inc.
Extensive stage small cell lung cancer is extremely aggressive sub-type of small cell lung cancer. Small cell lung itself is a sub-type of lung cancer which accounts for less than 20% cases. The treatment of extensive stage small cell lung cancer has been extremely challenging owing to poor survival rate of the patients.
The prevalence of extensive stage small lung cancer is estimated to increase in five of the seven major markets included in the study.
Our healthcare experts have found PD-1/PD-L1 immunotherapy to be one of the most rapidly adopted therapies, and the global market for PD-1/PD-L1 immunotherapy is predicted to grow at a CAGR of 10.72% over the forecast period of 2020-2030.
The global biomaterials market was valued at $122.92 billion in 2020 and is expected to reach $725.88 billion by 2031, growing at a CAGR of 17.98% between 2021 and 2031.
The global brain imaging modalities market report highlights that the market was valued at $12,334.2 million in 2021 and is expected to reach $20,209.2 million by the end of 2031. The market is expected to grow at a CAGR of 5.06% during the forecast period 2022-2031.
AI-Enabled Imaging Solutions Market - A Global Market Report by BIS ResearchBIS Research Inc.
The global AI-enabled medical imaging solutions market was valued at $1,854.5 million in 2022 and is anticipated to reach $18,356.5 million by 2032, witnessing a CAGR of 25.76% during the forecast period 2022-2032. you can get more info to visit this link..
https://bisresearch.com/industry-report/global-ai-enabled-medical-imaging-solutions-market.html
Precision cardiology industry to be one of the most rapidly evolving and dynamic markets and is predicted to grow at a CAGR of 12.90% over the forecast period of 2021-2031.
The Blood and Plasma Components Market size in 2020 was $39.58 billion and is expected to reach $66.47 billion in 2031, growing at a CAGR of 4.90% over the forecast period 2021-2031.
Pediatric Genetic Testing Market - Global Analysis & ForeacstBIS Research Inc.
A large number of companies are emerging and competing to establish their dominance in the global pediatric genetic testing market. The companies in the market are undergoing significant activities to expand their market presence and establish their position in the global market.
The global agricultural sensors market was valued at $4.18 billion in 2020, agricultural sensors industry is expected to grow with a CAGR of 15.4% and reach $9.79 billion by 2026.
View: https://bisresearch.com/industry-report/agricultural-sensors-market.html
Agricultural Sensors have a Wider Implication Across Various Farming PracticesAmanpreetSingh409
The global agricultural sensors market is expected to contribute to increased global food production as there is no dependence on arable land and climatic conditions, and year-round crop production can be achieved through these alternative farming techniques.
Read Report Overview: https://bisresearch.com/industry-report/agricultural-sensors-market.html
Agricultural Sensors Market: Applications and Global MarketsHarsh Singla
Sensors used in smart farming are known as agriculture sensors. These sensors provide data that assist farmers in monitoring and optimizing crops by adapting to changes in environmental conditions. By positioning sensors, farmers can examine crop health at a micro-scale, sustain resources, and reduce harsh environmental impact.
The global agricultural sensors market was valued at $4.18 billion in 2020, which is expected to grow with a CAGR of 15.4% and reach $9.79 billion by 2026.
To know more about Agricultural Sensors & its market, please follow the link given below:
https://bisresearch.com/industry-report/agricultural-sensors-market.html
To get the detailed report with excessive data on the Agricultural Sensors Market please follow the given link:
https://bisresearch.com/requestsample?id=1232&type=download
Toc- Agricultural Sensors Market to Reach $9.79 billion at CAGR of 15.4%Harsh Singla
The global agricultural sensors market was valued at $4.18 billion in 2020, which is expected to grow with a CAGR of 15.4% and reach $9.79 billion by 2026. North America was estimated to hold the highest share of about 24.0% in 2020, thereby accounting for a value of $1,003.9 million.
View the report of Agricultural Sensors Market made by the highly qualified research team of Bis Research:
https://bisresearch.com/industry-report/agricultural-sensors-market.html
Get the free sample of the Agricultural Sensors Industry Report exclusively on Bis Research’s Website:
https://bisresearch.com/requestsample?id=1232&type=download
The global agricultural sensors market was valued at $4.18 billion in 2020, which is expected to grow with a CAGR of 15.4% and reach $9.79 billion by 2026. The growth is primarily attributed to increased awareness of the benefits of alternative and optimized farming techniques that entail over conventional farming. The key sensor types are humidity sensor, mechanical sensor, water sensor, optical sensor, soil sensor, and others (livestock, electrochemical, pressure) which are being widely used in the agriculture sensors industry for water management, soil management, climate, and dairy management.
Get the Sample Report at: https://bit.ly/3jMLrAh
The sustainable masterbatches manufactured currently can withstand significantly higher temperatures as compared to their predecessors from over three to four years. Moreover, now the sustainable masterbatches are being used in agricultural and automotive industries as well.
Sustainable Masterbatch Market to reach $934.8 billion by 2025 and is anticipated to grow at a CAGR of 9.62% by 2025. Sustainable Masterbatch Industry is attributed due to the increased demand for bioplastics, biodegradable plastics.
Read Report Overview: https://bisresearch.com/industry-report/sustainable-masterbatch-market.html
Precision Pest Management Market Leading Players, Development and Demand Fore...BIS Research Inc.
While farmers are losing crops due to pests, they have pressure to increase food production to feed the growing world population.
Precision pest management (PPM) is very important to avoid destruction caused by pests and to increase productivity. PPM helps to detect pests early with the help of crop monitoring so they can be controlled early to avoid further losses. The availability of advanced technologies and equipment has made agriculture automation more prevalent in developed countries.
To know more about the in-depth insights on precision pest management market, get PDF document: https://bisresearch.com/requestsample?id=1404&type=download
Precision Pest Management Market is expected to reach $4,396.3 million by 2027. Purpose of precision pest management industry is to enhance the quality of crops.
Read Report Overview: https://bisresearch.com/industry-report/precision-pest-management-market.html
Cell and Gene Therapy Market - Growth Analysis & TrendsBIS Research Inc.
The cell and gene therapy industry analysis by BIS Research projects the market to grow at a significant CAGR of 36.52% during the forecast year 2019-25
The global precision medicine market is expected to reach $278.61 billion by the end of 2030. The market is projected to grow at a CAGR of 11.13% during the forecast period, 2020-2030.
The global precision medicine market is expected to reach $278.61 billion by the end of 2030. The market is projected to grow at a CAGR of 11.13% during the forecast period, 2020-2030.
Molecular Oncology Diagnostics Market Analysis and Forecast, 2022-2032BIS Research Inc.
The global molecular oncology diagnostics market was valued at $3,620.6 million in 2021 and is anticipated to reach $12,130.5 million by 2032, witnessing a CAGR of 11.43% during the forecast period 2022-2032.
The global gastrointestinal endoscopy market was valued at $13.40 billion in 2021 and is anticipated to reach $25.75 billion by 2031, witnessing a CAGR of 6.24% during the forecast period 2022-2031.
The market is driven by factors such as the increasing prevalence of gastrointestinal diseases, rising preference for minimally invasive surgeries, growing demand for capsule endoscopy, the shift from reusable endoscopes to disposable endoscopes, and technological advancements in the field of robot-assisted endoscopes and AI-based devices.
The global pharmacogenomics services market is projected to reach $9,346.8 million by 2031 from $5,060.0 million in 2020, at a CAGR of 5.71% during the forecast period 2021-2031.
Webinar Presentation Syndromic Testing – A New Take on Diagnosing Infectious ...BIS Research Inc.
The document summarizes a webinar on syndromic testing for diagnosing infectious diseases. The webinar featured several speakers who discussed topics like: how syndromic testing can provide faster results and reduce antibiotic use compared to traditional testing; applications of metagenomics next-generation sequencing (mNGS) in clinical diagnostics and its benefits; key trends in the syndromic testing market like high growth rates and the dominance of respiratory disease testing currently. The global syndromic testing market is expected to grow from $1.28 billion in 2022 to $3.25 billion in 2033, driven by factors like rising infectious disease incidence and the need for early diagnosis.
The global sustainable steel market is projected to reach $795.8 billion by 2031 from $327.3 billion in 2021, growing at a CAGR of 8.97% during the forecast period 2022-2031. The growth in the global sustainable steel market is expected to be driven by stringent government regulations, carbon neutrality targets, energy and cost efficiency owing to the use of recycled steel, and a significant increase in steel demand with the scarcity of raw materials and energy.
More Related Content
Similar to Global Viral and Non-Viral Vector Manufacturing Market
AI-Enabled Imaging Solutions Market - A Global Market Report by BIS ResearchBIS Research Inc.
The global AI-enabled medical imaging solutions market was valued at $1,854.5 million in 2022 and is anticipated to reach $18,356.5 million by 2032, witnessing a CAGR of 25.76% during the forecast period 2022-2032. you can get more info to visit this link..
https://bisresearch.com/industry-report/global-ai-enabled-medical-imaging-solutions-market.html
Precision cardiology industry to be one of the most rapidly evolving and dynamic markets and is predicted to grow at a CAGR of 12.90% over the forecast period of 2021-2031.
The Blood and Plasma Components Market size in 2020 was $39.58 billion and is expected to reach $66.47 billion in 2031, growing at a CAGR of 4.90% over the forecast period 2021-2031.
Pediatric Genetic Testing Market - Global Analysis & ForeacstBIS Research Inc.
A large number of companies are emerging and competing to establish their dominance in the global pediatric genetic testing market. The companies in the market are undergoing significant activities to expand their market presence and establish their position in the global market.
The global agricultural sensors market was valued at $4.18 billion in 2020, agricultural sensors industry is expected to grow with a CAGR of 15.4% and reach $9.79 billion by 2026.
View: https://bisresearch.com/industry-report/agricultural-sensors-market.html
Agricultural Sensors have a Wider Implication Across Various Farming PracticesAmanpreetSingh409
The global agricultural sensors market is expected to contribute to increased global food production as there is no dependence on arable land and climatic conditions, and year-round crop production can be achieved through these alternative farming techniques.
Read Report Overview: https://bisresearch.com/industry-report/agricultural-sensors-market.html
Agricultural Sensors Market: Applications and Global MarketsHarsh Singla
Sensors used in smart farming are known as agriculture sensors. These sensors provide data that assist farmers in monitoring and optimizing crops by adapting to changes in environmental conditions. By positioning sensors, farmers can examine crop health at a micro-scale, sustain resources, and reduce harsh environmental impact.
The global agricultural sensors market was valued at $4.18 billion in 2020, which is expected to grow with a CAGR of 15.4% and reach $9.79 billion by 2026.
To know more about Agricultural Sensors & its market, please follow the link given below:
https://bisresearch.com/industry-report/agricultural-sensors-market.html
To get the detailed report with excessive data on the Agricultural Sensors Market please follow the given link:
https://bisresearch.com/requestsample?id=1232&type=download
Toc- Agricultural Sensors Market to Reach $9.79 billion at CAGR of 15.4%Harsh Singla
The global agricultural sensors market was valued at $4.18 billion in 2020, which is expected to grow with a CAGR of 15.4% and reach $9.79 billion by 2026. North America was estimated to hold the highest share of about 24.0% in 2020, thereby accounting for a value of $1,003.9 million.
View the report of Agricultural Sensors Market made by the highly qualified research team of Bis Research:
https://bisresearch.com/industry-report/agricultural-sensors-market.html
Get the free sample of the Agricultural Sensors Industry Report exclusively on Bis Research’s Website:
https://bisresearch.com/requestsample?id=1232&type=download
The global agricultural sensors market was valued at $4.18 billion in 2020, which is expected to grow with a CAGR of 15.4% and reach $9.79 billion by 2026. The growth is primarily attributed to increased awareness of the benefits of alternative and optimized farming techniques that entail over conventional farming. The key sensor types are humidity sensor, mechanical sensor, water sensor, optical sensor, soil sensor, and others (livestock, electrochemical, pressure) which are being widely used in the agriculture sensors industry for water management, soil management, climate, and dairy management.
Get the Sample Report at: https://bit.ly/3jMLrAh
The sustainable masterbatches manufactured currently can withstand significantly higher temperatures as compared to their predecessors from over three to four years. Moreover, now the sustainable masterbatches are being used in agricultural and automotive industries as well.
Sustainable Masterbatch Market to reach $934.8 billion by 2025 and is anticipated to grow at a CAGR of 9.62% by 2025. Sustainable Masterbatch Industry is attributed due to the increased demand for bioplastics, biodegradable plastics.
Read Report Overview: https://bisresearch.com/industry-report/sustainable-masterbatch-market.html
Precision Pest Management Market Leading Players, Development and Demand Fore...BIS Research Inc.
While farmers are losing crops due to pests, they have pressure to increase food production to feed the growing world population.
Precision pest management (PPM) is very important to avoid destruction caused by pests and to increase productivity. PPM helps to detect pests early with the help of crop monitoring so they can be controlled early to avoid further losses. The availability of advanced technologies and equipment has made agriculture automation more prevalent in developed countries.
To know more about the in-depth insights on precision pest management market, get PDF document: https://bisresearch.com/requestsample?id=1404&type=download
Precision Pest Management Market is expected to reach $4,396.3 million by 2027. Purpose of precision pest management industry is to enhance the quality of crops.
Read Report Overview: https://bisresearch.com/industry-report/precision-pest-management-market.html
Cell and Gene Therapy Market - Growth Analysis & TrendsBIS Research Inc.
The cell and gene therapy industry analysis by BIS Research projects the market to grow at a significant CAGR of 36.52% during the forecast year 2019-25
The global precision medicine market is expected to reach $278.61 billion by the end of 2030. The market is projected to grow at a CAGR of 11.13% during the forecast period, 2020-2030.
The global precision medicine market is expected to reach $278.61 billion by the end of 2030. The market is projected to grow at a CAGR of 11.13% during the forecast period, 2020-2030.
Molecular Oncology Diagnostics Market Analysis and Forecast, 2022-2032BIS Research Inc.
The global molecular oncology diagnostics market was valued at $3,620.6 million in 2021 and is anticipated to reach $12,130.5 million by 2032, witnessing a CAGR of 11.43% during the forecast period 2022-2032.
The global gastrointestinal endoscopy market was valued at $13.40 billion in 2021 and is anticipated to reach $25.75 billion by 2031, witnessing a CAGR of 6.24% during the forecast period 2022-2031.
The market is driven by factors such as the increasing prevalence of gastrointestinal diseases, rising preference for minimally invasive surgeries, growing demand for capsule endoscopy, the shift from reusable endoscopes to disposable endoscopes, and technological advancements in the field of robot-assisted endoscopes and AI-based devices.
The global pharmacogenomics services market is projected to reach $9,346.8 million by 2031 from $5,060.0 million in 2020, at a CAGR of 5.71% during the forecast period 2021-2031.
Similar to Global Viral and Non-Viral Vector Manufacturing Market (20)
Webinar Presentation Syndromic Testing – A New Take on Diagnosing Infectious ...BIS Research Inc.
The document summarizes a webinar on syndromic testing for diagnosing infectious diseases. The webinar featured several speakers who discussed topics like: how syndromic testing can provide faster results and reduce antibiotic use compared to traditional testing; applications of metagenomics next-generation sequencing (mNGS) in clinical diagnostics and its benefits; key trends in the syndromic testing market like high growth rates and the dominance of respiratory disease testing currently. The global syndromic testing market is expected to grow from $1.28 billion in 2022 to $3.25 billion in 2033, driven by factors like rising infectious disease incidence and the need for early diagnosis.
The global sustainable steel market is projected to reach $795.8 billion by 2031 from $327.3 billion in 2021, growing at a CAGR of 8.97% during the forecast period 2022-2031. The growth in the global sustainable steel market is expected to be driven by stringent government regulations, carbon neutrality targets, energy and cost efficiency owing to the use of recycled steel, and a significant increase in steel demand with the scarcity of raw materials and energy.
Cybersecurity in Automotive Connected Vehicles and Growing Security Vulnerabi...BIS Research Inc.
• Agenda:
o To evaluate various security vulnerabilities in connected vehicles.
o To analyze the initiatives taken and regulations implemented to address security vulnerabilities.
o To analyze the various types of cybersecurity solutions being developed or offered for the security of connected vehicles.
o To evaluate the major players in the ecosystem.
Report Preview is available at: https://bisresearch.com/industry-report/global-automotive-cybersecurity-market.html
BIS Research conducted a webinar on Carbon Neutral Data Center PracticesBIS Research Inc.
Agenda:
To evaluate various emerging trends in Data center industry.
To analyze the initiatives taken and regulations implemented to increase sustainable practices.
To analyze the various types of technologies currently deployed.
To evaluate the major players in the ecosystem.
Speaker Profiles:
Name: JD Enright, Sr.
Designation: Chief Operating Officer
Company: TMGcore Inc.
Experienced and dedicated business professional with 29 years working with DOD, Multinational Private and Public sector organizations. Primary focus on developing and executing Strategic Step-Up Growth initiatives in Emerging Markets, and Technologies. Specialized leadership in developing improved business operations to include Financial and Operational efficiencies. Implementation of next generation HPC Platforms, Global Blockchain Development Strategies, Biotechnology, Viral Cell and Gene Therapies and Market Intelligence Assimilation for public applications.
Webinar by BIS Research on Precision Oncology BiomarkersBIS Research Inc.
Precision oncology biomarkers are essential tools for tailoring cancer treatment to individual patients, as they provide insights into tumor biology and guide the selection of targeted therapies.
BIS conducted a deep intelligence webinar on the state-of-the-art technologies and emerging strategies used through the precision oncology biomarkers.
Direct-to-Customer Wellness | A Webinar on the Growing Need for Personalized ...BIS Research Inc.
Direct-to-consumer (DTC) wellness testing industry witnessed a strong emphasis on consumer health and wellness, instigating industry stakeholders to discover new revenue streams.
As a leading market intelligence firm, BIS Research strives to stay on top of the latest emerging trends in the healthcare sector, among several other industry verticals. In the bid to do the same, BIS is conducting a deep intelligence webinar on the increasing focus of DTC wellness programs in the healthcare sector.
Read Related Reports Overview at:
https://bisresearch.com/industry-report/global-direct-to-consumer-genetic-testing-market.html
https://bisresearch.com/industry-report/us-dtc-wellness-testing-market.html
Emerging Battery Chemistries | Reimagining EVs Beyond Conventional Li-Ion Bat...BIS Research Inc.
The efficiency of the battery system in any electric vehicle (EV) determines its cost and vehicle performance. Challenges, such as range anxiety and charging time, have been a hindrance to increasing EV sales.
As a leading market intelligence firm, BIS Research strives to stay on top of the latest emerging technologies in the mobility sector, among several other industry verticals.
In the bid to do the same, BIS is conducting a deep intelligence webinar on the current paradigm shift happening for battery technologies in electric vehicles.
Here are all the details:
Webinar Topic: Emerging Battery Chemistries | Reimagining EVs Beyond Conventional Li-Ion Batteries
Webinar on AI in Medical Diagnosis with Emerging TechnologiesBIS Research Inc.
Artificial Intelligence (AI) is a rapidly growing field that has the potential to revolutionize the way medical diagnosis is performed. AI systems use advanced algorithms to analyze large amounts of data, such as medical images, patient histories, and lab results, to identify patterns and make predictions about patient outcomes.
In medical diagnosis, AI can be used in a variety of ways, including medical imaging, disease diagnosis, personalized treatment planning, and early disease detection. By leveraging the power of AI, healthcare providers can make faster and more accurate diagnoses, resulting in better patient outcomes.
Agenda:
The main agenda of this webinar is to understand and explore the following:
• Policy implications related to AI and digital transformation in healthcare.
• Initiatives taken and regulations implemented to address cybersecurity concerns.
• Major factors driving and hindering the growth of AI in medical devices diagnosis.
• Major players in the ecosystem
The global demand for achieving the net zero emission target by 2050 has pushed governments all over to adapt and adopt advanced carbon removal technologies to go carbon negative.
It is, indeed, an important topic of discussion, because a carbon free environment is the need of the hour to save our planet. And, therefore, BIS Research is glad to announce its upcoming webinar on this particular subject.
Agenda:
The main agenda of this webinar is to understand and explore the following:
• Primary sources of carbon emissions and associated environmental issues
• Carbon dioxide removal – key technology and adoption scenario
• Carbon dioxide removal (CDR): trends and key market developments
• Carbon dioxide removal as a credible solution
• Conclusion and future outlook
Webinar on Biomanufacturing 4.0 – A New Era in Cell and Gene Therapy DevelopmentBIS Research Inc.
Agenda of the Webinar:
Cell and Gene Therapy Biomanufacturing Market: Trends and Key Developments
Awaited Technologies in the Cell and Gene Therapy Development
Regulatory Scenario – GMP/cGMP Guidelines
Biomanufacturing 4.0 - Adoption Scenario
Conclusion and Future Outlook
Sub-Orbital Testing Services Market Future Growth and Business Opportunities ...BIS Research Inc.
Sub-orbital platforms are increasing access to the near space-like environment for end users such as government agencies, research institutions, and commercial players.
The competitive landscape of the sub-orbital testing services market consists of several organic and inorganic strategies followed by the key players to increase their market share.
The space industry is continuously innovating and developing advanced technologies with the objective of enhancing space capabilities. The industry is gearing up to develop vehicles that entail a major feature, i.e., reusability.
Request for the sample of the report at: https://bisresearch.com/requestsample?id=1442&type=download
TOC - Global Military Robotic and Autonomous Systems (RAS) Market.pdfBIS Research Inc.
The robotic and autonomous system (RAS) is a multidisciplinary scientific and technological domain for implementing complex systems with cognitive capabilities.
RAS in military is being rigorously introduced and used in combat training. This has boosted the capabilities of armed units and subunits. The advent of artificial intelligence (AI) and its integration with military RAS has the potential to change future warfare.
Growing demand to increase warfighter lethality and remove soldiers from dangerous situations is propelling the global military RAS market.
Request for the sample of the report at: https://bisresearch.com/requestsample?id=1442&type=download
UAV Propulsion System Market Analysis, Statistics, Regional, and Forecast to ...BIS Research Inc.
UAV propulsion system manufacturers have also been inclined to counter the environment and other government regulations by developing sustainable propulsion, i.e., steps toward fossil-free aviation fuels and ion propulsion are a few of such significant innovations.
UAVs can be powered by a variety of different types of engines, including piston engines, turbine engines, Wankel engines, and electric and solar-powered engines.
The global UAV propulsion system market has witnessed a high growth rate in the last five to six years owing to its widespread applications across various industries, which were further bolstered by the COVID-19 pandemic.
Publication of BIS Research on UAV Propulsion System market has some great insights for UAV Propulsion Systems. Get free sample here: https://bisresearch.com/requestsample?id=1443&type=download
Fleet Management Market Trends, Key Players, Industry Analysis and Forecast 2...BIS Research Inc.
A fleet management system, which includes hardware, software and service, has the ability to make decisions for fleet managers and fleet businesses easily.
The ongoing research and development activities in this market are experiencing product launches of fleet management system for fleet owners, fleet managers, or businesses that utilize fleet management on a daily basis.
BIS Research has a new publication on Fleet Management, view free sample here : https://bisresearch.com/requestsample?id=1444&type=download
Agenda:
The main agenda of this webinar is to understand and explore the following:
• LoRaWAN adoption in agricultural applications as well as understanding the trends and key market developments.
• The significance of LoRaWAN in the field of IoT
• A comparative analysis between LoRaWAN and other IoT networks in terms of technology and capabilities.
• The impact of LoRaWAN on the operations of the agriculture industry and common use cases.
• The impact of the implementation of LoRaWAN technology on stakeholders in the agriculture ecosystem.
• The potential challenges that LoRaWAN might face in the future.
• The competitiveness of the market for LoRaWAN technology.
Augmented Reality in Agriculture Analysis and Statistics from 2022-2027BIS Research Inc.
AR depicts superimposing visual, audio, or other sensory data onto the physical world to improve one's experience. It is one of the most popular technological trends in today’s times. AR images can be displayed on a variety of devices, including eyeglasses and goggles, headsets, and heads-up displays such as helmet visors. As more smartphones, tablets, and other handheld devices that support AR are becoming available globally, the most popular way to use AR is on these devices in a variety of apps and games.
Although AR is used to visually communicate information, it is the integration of AR with other technologies that make it possible to adapt to precision farming and visual-based operations. Hence, farmers can utilize AR in combination with other technologies such as artificial intelligence (AI), big data, and the Internet of Things (IoT) to manage the rising food demand.
Get Augmented Reality in Agriculture report overview at: https://bisresearch.com/industry-report/ar-agriculture-market.html
Smart Harvest Market Generated Opportunities, Future Scope 2022-2027BIS Research Inc.
The growth in the global smart harvest market is expected to be driven by increasing smart farming practices among farmers, labor shortage, and growing government support for promoting the use of smart tech in the agriculture industry. Supported by government policies and technological developments, farmers and growers across the globe are expected to increase the implementation of smart harvest technologies. Moreover, the smart harvest market is witnessing several upcoming trends and opportunities, further propelling growth in the industry.
Get the PDF document on the technical aspects of Smart Harvest Market at: https://bisresearch.com/requestsample?id=1386&type=download
Agriculture Drones and Robots Market Growth Opportunity, Trends, Demand Analy...BIS Research Inc.
Agriculture drones and robots offer multiple benefits over conventional farming equipment, which is another factor driving the demand for these products in the agriculture industry. The adoption of agriculture drones and robots in commercial farms offers huge cost-saving opportunities.
Request for the Sample of the Report at: https://bisresearch.com/requestsample?id=1425&type=download
Next-Generation Automotive Lighting Industry to See Significant Growth During...BIS Research Inc.
Since the inception of automotive vehicles amongst the masses, automotive lighting has witnessed significant growth owing to the growing safety apprehensions revolving around vehicles.
The rapid technical progress in the automotive lighting field shows that basic light sources based on incandescent and gas-release bulbs have shifted to modern-day technologies such as light-emitting diodes (LEDs), laser technology, and organic light-emitting diodes (OLEDs).
Get the Sample of the Report containing the information on various technical aspects at: https://bisresearch.com/requestsample?id=1435&type=download
Automotive Cybersecurity Market Current Trends And Restraints Forecast 2031BIS Research Inc.
Automotive Cybersecurity Market - A Global and Regional Analysis Focus on Product, Application, and Country Analysis - Analysis and Forecast, 2022-2031.
The increase in the connectivity of a vehicle’s center control module has increased the vehicle’s vulnerability to cyberattacks with less safety and security.
Request for the sample report at: https://bisresearch.com/requestsample?id=1436&type=download
Gemma Wean- Nutritional solution for Artemiasmuskaan0008
GEMMA Wean is a high end larval co-feeding and weaning diet aimed at Artemia optimisation and is fortified with a high level of proteins and phospholipids. GEMMA Wean provides the early weaned juveniles with dedicated fish nutrition and is an ideal follow on from GEMMA Micro or Artemia.
GEMMA Wean has an optimised nutritional balance and physical quality so that it flows more freely and spreads readily on the water surface. The balance of phospholipid classes to- gether with the production technology based on a low temperature extrusion process improve the physical aspect of the pellets while still retaining the high phospholipid content.
GEMMA Wean is available in 0.1mm, 0.2mm and 0.3mm. There is also a 0.5mm micro-pellet, GEMMA Wean Diamond, which covers the early nursery stage from post-weaning to pre-growing.
We are one of the top Massage Spa Ajman Our highly skilled, experienced, and certified massage therapists from different corners of the world are committed to serving you with a soothing and relaxing experience. Luxuriate yourself at our spas in Sharjah and Ajman, which are indeed enriched with an ambiance of relaxation and tranquility. We could confidently claim that we are one of the most affordable Spa Ajman and Sharjah as well, where you can book the massage session of your choice for just 99 AED at any time as we are open 24 hours a day, 7 days a week.
Visit : https://massagespaajman.com/
Call : 052 987 1315
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
Exploring the Benefits of Binaural Hearing: Why Two Hearing Aids Are Better T...Ear Solutions (ESPL)
Binaural hearing using two hearing aids instead of one offers numerous advantages, including improved sound localization, enhanced sound quality, better speech understanding in noise, reduced listening effort, and greater overall satisfaction. By leveraging the brain’s natural ability to process sound from both ears, binaural hearing aids provide a more balanced, clear, and comfortable hearing experience. If you or a loved one is considering hearing aids, consult with a hearing care professional at Ear Solutions hearing aid clinic in Mumbai to explore the benefits of binaural hearing and determine the best solution for your hearing needs. Embracing binaural hearing can lead to a richer, more engaging auditory experience and significantly improve your quality of life.
Unlocking the Secrets to Safe Patient Handling.pdfLift Ability
Furthermore, the time constraints and workload in healthcare settings can make it challenging for caregivers to prioritise safe patient handling Australia practices, leading to shortcuts and increased risks.
The facial nerve, also known as cranial nerve VII, is one of the 12 cranial nerves originating from the brain. It's a mixed nerve, meaning it contains both sensory and motor fibres, and it plays a crucial role in controlling various facial muscles, as well as conveying sensory information from the taste buds on the anterior two-thirds of the tongue.
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDr Rachana Gujar
Introduction: Substance use education is crucial due to its prevalence and societal impact.
Alcohol Use: Immediate and long-term risks include impaired judgment, health issues, and social consequences.
Tobacco Use: Immediate effects include increased heart rate, while long-term risks encompass cancer and heart disease.
Drug Use: Risks vary depending on the drug type, including health and psychological implications.
Prevention Strategies: Education, healthy coping mechanisms, community support, and policies are vital in preventing substance use.
Harm Reduction Strategies: Safe use practices, medication-assisted treatment, and naloxone availability aim to reduce harm.
Seeking Help for Addiction: Recognizing signs, available treatments, support systems, and resources are essential for recovery.
Personal Stories: Real stories of recovery emphasize hope and resilience.
Interactive Q&A: Engage the audience and encourage discussion.
Conclusion: Recap key points and emphasize the importance of awareness, prevention, and seeking help.
Resources: Provide contact information and links for further support.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
2024 HIPAA Compliance Training Guide to the Compliance OfficersConference Panel
Join us for a comprehensive 90-minute lesson designed specifically for Compliance Officers and Practice/Business Managers. This 2024 HIPAA Training session will guide you through the critical steps needed to ensure your practice is fully prepared for upcoming audits. Key updates and significant changes under the Omnibus Rule will be covered, along with the latest applicable updates for 2024.
Key Areas Covered:
Texting and Email Communication: Understand the compliance requirements for electronic communication.
Encryption Standards: Learn what is necessary and what is overhyped.
Medical Messaging and Voice Data: Ensure secure handling of sensitive information.
IT Risk Factors: Identify and mitigate risks related to your IT infrastructure.
Why Attend:
Expert Instructor: Brian Tuttle, with over 20 years in Health IT and Compliance Consulting, brings invaluable experience and knowledge, including insights from over 1000 risk assessments and direct dealings with Office of Civil Rights HIPAA auditors.
Actionable Insights: Receive practical advice on preparing for audits and avoiding common mistakes.
Clarity on Compliance: Clear up misconceptions and understand the reality of HIPAA regulations.
Ensure your compliance strategy is up-to-date and effective. Enroll now and be prepared for the 2024 HIPAA audits.
Enroll Now to secure your spot in this crucial training session and ensure your HIPAA compliance is robust and audit-ready.
https://conferencepanel.com/conference/hipaa-training-for-the-compliance-officer-2024-updates
2024 HIPAA Compliance Training Guide to the Compliance Officers
Global Viral and Non-Viral Vector Manufacturing Market
1. res
Focus on Vector Type, Application,
Disease and Region
Analysis and Forecast: 2021-2031
December 2021
Global Viral and
Non-Viral Vector
Manufacturing
Market
Table of Content
3. 2
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Table of Content
Executive Summary..........................................................................26
1. Product Definition......................................................................36
1.1 Product Definition............................................................................................36
2. Scope of Study...........................................................................37
2.1 Overview...........................................................................................................37
2.2 Segmentation of the Global Viral and Non-Viral Vector Manufacturing
Market ...............................................................................................................38
2.3 Assumptions and Limitations.........................................................................38
2.4 Key Questions Answered in This Report.......................................................39
2.5 Base Year and Forecast Period......................................................................40
3. Research Methodology ..............................................................41
3.1 Overview...........................................................................................................41
4. Global Viral and Non-Viral Vector Manufacturing: Market
Overview ...................................................................................47
4.1 Market Overview ..............................................................................................47
4.2 Introduction to Vectors ...................................................................................48
4.3 Importance of Vectors.....................................................................................49
4.3.1 Viral Vectors ................................................................................................50
4.3.2 Non-Viral Vectors ........................................................................................51
4.4 Major Milestones in Vector Manufacturing....................................................52
4.4.1 Manufacturing Process...............................................................................52
4.4.1.1 Upstream Bioprocessing.................................................................................... 52
4.4.1.2 Downstream Bioprocessing............................................................................... 53
4.5 Global Viral and Non-Viral Vector Manufacturing Market Size ....................54
4.6 Impact of COVID-19 on the Global Viral and Non-Viral Vector
Manufacturing Market .....................................................................................55
4.6.1 Disruption of the Vector Manufacturing Industry Due to COVID-19
Crisis ............................................................................................................55
4.6.2 COVID-19 Affecting the Supply Chain of Vector-Based Therapies.........57
4. 3
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
4.6.2.1 Effect on Cell Therapy ....................................................................................... 58
4.6.2.2 Effect on Gene Therapy..................................................................................... 59
4.6.3 Interruption in Research and Clinical Development and Commercial
Operation .....................................................................................................60
4.6.3.1 Research and Clinical Development.................................................................. 60
4.6.3.2 Commercial Operation and Access ................................................................... 60
4.6.4 Effect of COVID-19 in Vaccine Manufacturing ..........................................61
4.6.5 Measures Taken to Address the Current Problem ...................................64
4.6.6 Navigating Crisis Recovery and Looking to the Future...........................65
5. Market Dynamics .......................................................................67
5.1 Impact Analysis ...............................................................................................67
5.2 Overview...........................................................................................................67
5.3 Market Drivers..................................................................................................68
5.3.1 Viral Vectors ................................................................................................68
5.3.1.1 Rapid Uptake of Viral Vector to Develop Innovative Therapies......................... 68
5.3.1.2 Increasing Number of Clinical Studies for the Development of Gene
Therapy ................................................................................................... 69
5.3.1.3 Favorable Funding Scenario for Vector-Based Therapies................................. 70
5.3.2 Non-Viral Vectors ........................................................................................71
5.3.2.1 Increasing Adoption of Nucleic Acid Therapeutics ............................................ 71
5.3.2.2 Rise in Synergistic Activities in the Market ........................................................ 71
5.4 Market Restraints.............................................................................................72
5.4.1 Viral Vectors ................................................................................................72
5.4.1.1 Unaffordable Cost of Gene Therapy.................................................................. 72
5.4.1.2 High Manufacturing Cost of Viral Vectors.......................................................... 73
5.4.1.3 Complications Associated with Large-Scale Production of Viral Vectors .......... 74
5.4.2 Non-Viral Vectors ........................................................................................74
5.4.2.1 Low Transfection Efficiency............................................................................... 74
5.5 Market Opportunities.......................................................................................75
5.5.1 Viral Vectors ................................................................................................75
5.5.1.1 Rise in Demand for Synthetic Genes................................................................. 75
5.5.1.2 Emergence of Next-Generation Vectors............................................................ 75
5. 4
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
5.5.2 Non-Viral Vectors ........................................................................................76
5.5.2.1 Limitation of Viral Vectors.................................................................................. 76
6. Industry Analysis .......................................................................77
6.1 Overview...........................................................................................................77
6.2 Regulatory Scenario........................................................................................79
6.3 Patent Landscape............................................................................................82
7. Competitive Landscape .............................................................86
7.1 Overview...........................................................................................................86
7.2 Key Development and Strategies...................................................................87
7.2.1 Synergistic Activities ..................................................................................88
7.2.2 Business Expansion ...................................................................................89
7.2.3 Product Launches .......................................................................................90
7.2.4 Mergers and Acquisitions...........................................................................90
7.2.5 Other Development .....................................................................................91
7.3 Market Share Analysis (by Company), 2020..................................................92
7.4 Growth Share Analysis ...................................................................................94
7.4.1 Growth Share Analysis of the Global Viral and Non-Viral Vector
Manufacturing Market (by Company) ........................................................94
7.4.2 Growth Share Analysis of the Global Viral and Non-Viral Vector
Manufacturing Market (by Vector Type) ....................................................95
8. Global Viral and Non-Viral Vector Manufacturing Market (by
Vector Type)..............................................................................97
8.1 Overview...........................................................................................................97
8.2 Viral Vector.......................................................................................................99
8.2.1 Adenoviral Vector......................................................................................102
8.2.2 Retroviral Vector........................................................................................104
8.2.3 Adeno-Associated Viral Vector ................................................................105
8.2.4 Lentiviral Vector ........................................................................................106
8.2.5 Vaccinia Viral Vector.................................................................................108
8.2.6 Other Viral Vector......................................................................................109
6. 5
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
8.3 Non-Viral Vectors...........................................................................................110
8.3.1 Plasmid DNA..............................................................................................111
8.3.2 Lipid-Based Non-Viral Vector...................................................................113
8.3.3 Polymer-Based Non-Viral Vector .............................................................114
8.3.4 Other Non-Viral Vector (Peptide-Based and Hybrid/Combination) .......116
9. Global Viral and Non-Viral Vector Manufacturing Market (by
Disease) ..................................................................................118
9.1 Overview.........................................................................................................118
9.2 Cancer ............................................................................................................120
9.3 Genetic Disease.............................................................................................122
9.4 Infectious Disease .........................................................................................123
9.5 Cardiovascular Disease ................................................................................125
9.6 Other Diseases...............................................................................................127
10. Global Viral and Non-Viral Vector Manufacturing Market (by
Application).............................................................................129
10.1 Overview.........................................................................................................129
10.2 Gene Therapy.................................................................................................131
10.2.1 Viral Vector ................................................................................................132
10.2.2 Non-Viral Vector ........................................................................................134
10.3 Vaccinology....................................................................................................136
10.3.1 Viral Vector ................................................................................................138
10.3.2 Non-Viral Vector ........................................................................................139
10.4 Cell Therapy ...................................................................................................140
10.4.1 Viral Vector ................................................................................................142
10.4.2 Non-Viral Vector ........................................................................................143
10.5 Other Applications.........................................................................................144
10.5.1 Viral Vector ................................................................................................145
10.5.2 Non-Viral Vector ........................................................................................146
11. Global Viral and Non-Viral Vector Manufacturing Market (by
Region)....................................................................................147
7. 6
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
11.1 Overview.........................................................................................................147
11.2 North America................................................................................................148
11.2.1 Overview ....................................................................................................148
11.2.2 U.S. .............................................................................................................149
11.2.2.1 Viral Vector ...................................................................................................... 151
11.2.2.2 Non-Viral Vector .............................................................................................. 152
11.2.3 Canada .......................................................................................................153
11.2.3.1 Viral Vector ...................................................................................................... 154
11.2.3.2 Non-Viral Vector .............................................................................................. 155
11.3 Europe ............................................................................................................156
11.3.1 Overview ....................................................................................................156
11.3.2 Germany.....................................................................................................157
11.3.2.1 Viral Vector ...................................................................................................... 158
11.3.2.2 Non-Viral Vector .............................................................................................. 159
11.3.3 U.K. .............................................................................................................160
11.3.3.1 Viral Vector ...................................................................................................... 161
11.3.3.2 Non-Viral Vector .............................................................................................. 162
11.3.4 France.........................................................................................................163
11.3.4.1 Viral Vector ...................................................................................................... 164
11.3.4.2 Non-Viral Vector .............................................................................................. 165
11.3.5 Italy .............................................................................................................166
11.3.5.1 Viral Vector ...................................................................................................... 167
11.3.5.2 Non-Viral Vector .............................................................................................. 168
11.3.6 Switzerland ................................................................................................168
11.3.6.1 Viral Vector ...................................................................................................... 170
11.3.6.2 Non-Viral Vector .............................................................................................. 171
11.3.7 Belgium ......................................................................................................171
11.3.7.1 Viral Vector ...................................................................................................... 173
11.3.7.2 Non-Viral Vector .............................................................................................. 173
11.3.8 Spain...........................................................................................................174
11.3.8.1 Viral Vector ...................................................................................................... 175
8. 7
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
11.3.8.2 Non-Viral Vector .............................................................................................. 176
11.3.9 Rest-of-Europe...........................................................................................176
11.3.9.1 Viral Vector ...................................................................................................... 178
11.3.9.2 Non-Viral Vector .............................................................................................. 178
11.4 Asia-Pacific ....................................................................................................179
11.4.1 Overview ....................................................................................................179
11.4.2 China ..........................................................................................................180
11.4.2.1 Viral Vector ...................................................................................................... 182
11.4.2.2 Non-Viral Vector .............................................................................................. 182
11.4.3 Australia.....................................................................................................183
11.4.3.1 Viral Vector ...................................................................................................... 185
11.4.3.2 Non-Viral Vector .............................................................................................. 185
11.4.4 Japan..........................................................................................................186
11.4.4.1 Viral Vector ...................................................................................................... 187
11.4.4.2 Non-Viral Vector .............................................................................................. 188
11.4.5 India............................................................................................................188
11.4.5.1 Viral Vector ...................................................................................................... 190
11.4.5.2 Non-Viral Vector .............................................................................................. 191
11.4.6 South Korea ...............................................................................................191
11.4.6.1 Viral Vector ...................................................................................................... 193
11.4.6.2 Non-Viral Vector .............................................................................................. 193
11.4.7 Singapore...................................................................................................194
11.4.7.1 Viral Vector ...................................................................................................... 195
11.4.7.2 Non-Viral Vector .............................................................................................. 196
11.4.8 Rest-of-Asia-Pacific...................................................................................196
11.4.8.1 Viral Vector ...................................................................................................... 197
11.4.8.2 Non-Viral Vector .............................................................................................. 198
11.5 Rest-of-the-World ..........................................................................................199
11.5.1 Overview ....................................................................................................199
11.5.1.1 Viral Vector ...................................................................................................... 200
11.5.1.2 Non-Viral Vector .............................................................................................. 201
9. 8
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
12. Company Profiles.....................................................................202
12.1 Overview.........................................................................................................202
12.2 Boehringer Ingelheim....................................................................................203
12.2.1 Company Overview ...................................................................................203
12.2.1.1 Role of Boehringer Ingelheim in the Global Viral and Non-Viral Vector
Manufacturing Market............................................................................ 203
12.2.1.2 Product Portfolio .............................................................................................. 203
12.2.2 SWOT Analysis..........................................................................................204
12.3 Catalent, Inc. ..................................................................................................205
12.3.1 Company Overview ...................................................................................205
12.3.1.1 Role of Catalent, Inc. in the Global Viral and Non-Viral Vector
Manufacturing Market............................................................................ 205
12.3.1.2 Product Portfolio .............................................................................................. 206
12.3.2 Financials...................................................................................................207
12.3.3 Key Insights about Financial Health of the Company............................208
12.3.4 SWOT Analysis..........................................................................................209
12.4 FUJIFILM Holdings Corporation...................................................................210
12.4.1 Company Overview ...................................................................................210
12.4.1.1 Role of FUJIFILM Holdings Corporation in the Global Viral and Non-Viral
Vector Manufacturing Market ................................................................ 210
12.4.1.2 Product Portfolio .............................................................................................. 211
12.4.2 Financials...................................................................................................211
12.4.3 Key Insights about Financial Health of the Company............................213
12.4.4 SWOT Analysis..........................................................................................214
12.5 Danaher Corporation.....................................................................................215
12.5.1 Company Overview ...................................................................................215
12.5.2 Role of Danaher Corporation in the Global Viral and Non-Viral
Vector Manufacturing Market ...................................................................215
12.5.2.1 Product Portfolio .............................................................................................. 216
12.5.3 Financials...................................................................................................217
12.5.4 Key Insights about Financial Health of the Company............................218
12.5.5 SWOT Analysis..........................................................................................219
10. 9
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
12.6 Genscript Biotech Corporation ....................................................................220
12.6.1 Company Overview ...................................................................................220
12.6.1.1 Role of Genscript Biotech Corporation in the Global Viral and Non-Viral
Vector Manufacturing Market ................................................................ 220
12.6.1.2 Product Portfolio .............................................................................................. 221
12.6.2 Financials...................................................................................................221
12.6.3 Key Insights about Financial Health of the Company............................223
12.6.4 SWOT Analysis..........................................................................................224
12.7 Lonza Group AG ............................................................................................225
12.7.1 Company Overview ...................................................................................225
12.7.1.1 Role of Lonza Group AG in the Global Viral and Non-Viral Vector
Manufacturing Market............................................................................ 225
12.7.1.2 Product Portfolio .............................................................................................. 226
12.7.2 Financials...................................................................................................226
12.7.3 Key Insights about Financial Health of the Company............................228
12.7.4 SWOT Analysis..........................................................................................229
12.8 Merck KGaA Inc. ............................................................................................230
12.8.1 Company Overview ...................................................................................230
12.8.1.1 Role of Merck KGaA Inc. in the Global Viral and Non-Viral Vector
Manufacturing Market............................................................................ 230
12.8.1.2 Product Portfolio .............................................................................................. 231
12.8.2 Financials...................................................................................................231
12.8.3 Key Insights about Financial Health of the Company............................233
12.8.4 SWOT Analysis..........................................................................................233
12.9 Oxford Biomedica plc....................................................................................234
12.9.1 Company Overview ...................................................................................234
12.9.1.1 Role of Oxford Biomedica plc in the Global Viral and Non-Viral Vector
Manufacturing Market............................................................................ 234
12.9.1.2 Product Portfolio .............................................................................................. 235
12.9.2 Financials...................................................................................................235
12.9.3 Key Insights about Financial Health of the Company............................237
12.9.4 SWOT Analysis..........................................................................................238
11. 10
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
12.10 Sartorius AG...................................................................................................239
12.10.1 Company Overview.............................................................................239
12.10.1.1 Role of Sartorius AG in the Global Viral and Non-Viral Vector
Manufacturing Market............................................................................ 239
12.10.1.2 Product Portfolio .............................................................................................. 240
12.10.2 Financials ............................................................................................240
12.10.3 Key Insights about Financial Health of the Company......................242
12.10.4 SWOT Analysis....................................................................................243
12.11 Takara Bio Inc. ...............................................................................................244
12.11.1 Company Overview.............................................................................244
12.11.1.1 Role of Takara Bio Inc. in the Global Viral and Non-Viral Vector
Manufacturing Market............................................................................ 244
12.11.1.2 Product Portfolio .............................................................................................. 245
12.11.2 Financials ............................................................................................245
12.11.3 Key Insights about Financial Health of the Company......................247
12.11.4 SWOT Analysis....................................................................................248
12.12 Thermo Fisher Scientific Inc.........................................................................249
12.12.1 Company Overview.............................................................................249
12.12.1.1 Role of Thermo Fisher Scientific, Inc. in the Global Viral and Non-Viral
Vector Manufacturing Market ................................................................ 249
12.12.1.2 Product Portfolio .............................................................................................. 250
12.12.2 Financials ............................................................................................251
12.12.3 Key Insights about Financial Health of the Company......................252
12.12.4 SWOT Analysis....................................................................................253
12.13 Wuxi AppTec..................................................................................................254
12.13.1 Company Overview.............................................................................254
12.13.1.1 Role of Wuxi AppTec in Global Viral and Non-Viral Vector Manufacturing
Market.................................................................................................... 254
12.13.1.2 Product Portfolio .............................................................................................. 255
12.13.2 Financials ............................................................................................255
12.13.3 Key Insights about Financial Health of the Company......................257
12.13.4 SWOT Analysis....................................................................................258
12. 11
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
12.14 Acuitas Therapeutics ....................................................................................259
12.14.1 Company Overview.............................................................................259
12.14.1.1 Role of Acuitas Therapeutics in the Global Viral and Non-Viral Vector
Manufacturing Market............................................................................ 259
12.14.1.2 Product Portfolio .............................................................................................. 259
12.14.2 SWOT Analysis....................................................................................260
12.15 Evonik Industries AG ....................................................................................261
12.15.1 Company Overview.............................................................................261
12.15.1.1 Role of Evonik Industries AG in the Global Viral and Non-Viral Vector
Manufacturing Market............................................................................ 261
12.15.1.2 Product Portfolio .............................................................................................. 262
12.15.2 Financials ............................................................................................262
12.15.3 Key Insights about Financial Health of the Company......................264
12.15.4 SWOT Analysis....................................................................................265
12.16 Exelead, Inc....................................................................................................266
12.16.1 Company Overview.............................................................................266
12.16.1.1 Role of Exelead, Inc. in the Global Viral and Non-Viral Vector
Manufacturing Market............................................................................ 266
12.16.1.2 Product Portfolio .............................................................................................. 266
12.16.2 SWOT Analysis....................................................................................267
12.17 Entos Pharmaceuticals .................................................................................268
12.17.1 Company Overview.............................................................................268
12.17.1.1 Role of Entos Pharmaceuticals in the Global Viral and Non-Viral Vector
Manufacturing Market............................................................................ 268
12.17.1.2 Product Portfolio .............................................................................................. 268
12.17.2 SWOT Analysis....................................................................................269
12.18 Genevant Sciences GmbH ............................................................................270
12.18.1 Company Overview.............................................................................270
12.18.1.1 Role of Genevant Sciences GmbH in the Global Viral and Non-Viral
Vector Manufacturing Market ................................................................ 270
12.18.1.2 Product Portfolio .............................................................................................. 270
12.18.2 SWOT Analysis....................................................................................271
13. 12
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
12.19 T&T Scientific Corporation ...........................................................................272
12.19.1 Company Overview.............................................................................272
12.19.1.1 Role of T&T Scientific Corporation in the Global Viral and Non-Viral
Vector Manufacturing Market ................................................................ 272
12.19.1.2 Product Portfolio .............................................................................................. 272
12.19.2 SWOT Analysis....................................................................................273
12.20 Moderna, Inc...................................................................................................274
12.20.1 Company Overview.............................................................................274
12.20.1.1 Role of Moderna, Inc. in the Global Viral and Non-Viral Vector
Manufacturing Market............................................................................ 274
12.20.1.2 Product Portfolio .............................................................................................. 275
12.20.2 Financials ............................................................................................276
12.20.3 Key Insights about Financial Health of the Company......................277
12.20.4 SWOT Analysis....................................................................................278
12.21 CureVac N.V. ..................................................................................................279
12.21.1 Company Overview.............................................................................279
12.21.1.1 Role of CureVac N.V in the Global Viral and Non-Viral Vector
Manufacturing Market............................................................................ 279
12.21.1.2 Product Portfolio .............................................................................................. 279
12.21.2 Financials ............................................................................................280
12.21.3 Key Insights about Financial Health of the Company......................281
12.21.4 SWOT Analysis....................................................................................282
14. 13
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
List of Figures
Figure 1: Global Viral and Non-Viral Vector Manufacturing Market (by Region), 2020 and 2031
Figure 2: Key Players of the Global Viral and Non-Viral Vector Manufacturing Market
Figure 3: Drivers, Challenges, and Opportunities of the Global Viral Vector and Non-Viral Vector
Manufacturing Market
Figure 4: Share of Key Developments and Strategies, January 2018-October 2021
Figure 5: Global Viral and Non-Viral Vector Manufacturing Market (by Vector Type), $Million, 2020
and 2031
Figure 6: Global Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031
Figure 7: Global Viral and Non-Viral Vector Manufacturing Market (by Disease), 2020 and 2031
Figure 8: Global Viral and Non-Viral Vector Manufacturing Market (by Application), 2020 and 2031
Figure 9: Global Viral and Non-Viral Vector Manufacturing Market Segmentation
Figure 10: Global Viral and Non-Viral Vector Manufacturing Market Research Methodology
Figure 11: Primary Research
Figure 12: Secondary Research
Figure 13: Data Triangulation
Figure 14: Bottom-Up Approach (Segment-Wise Analysis)
Figure 15: Top-Down Approach (Segment-Wise Analysis)
Figure 16: Assumptions and Limitations
Figure 17: Mechanism of Action of Vectors
Figure 18: Evolutionary History of Vectors
Figure 19: Typical Production Methods of Viral Vectors and Plasmids
Figure 20: Global Viral and Non-Viral Vector Manufacturing Market, $Billion, 2020-2031
Figure 21: Pre- COVID-19 and Post-COVID-19 Scenario of the Global Viral and Non-Viral Vector
Manufacturing Market, 2017-2025
Figure 22: Long, Complex, and Highly Controlled Supply Chain of Cell Therapy
Figure 23: Less-Complex Supply Chain of Gene Therapy
Figure 24: Areas of Disruption in Cell Therapy Industry
Figure 25: Areas of Disruption in Gene Therapy Industry
Figure 26: Key Areas of Disruption in Commercial Operation
Figure 27: Measures to Navigate Crisis Recovery
Figure 28: Impact Analysis
Figure 29: Workflow Associated with Biomanufacturing for the Commercialization of Viral and Non-
Viral Vector Products
Figure 30: Competitive Landscape, January 2018-October 2021
Figure 31: Share of Key Development and Strategy, January 2018-October 2021
Figure 32: Share of Synergistic Activities (by Company), January 2018-October 2021
15. 14
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Figure 33: Share of Business Expansion Activities (by Company), January 2018-October 2021
Figure 34: Share of Product Launches (by Company), January 2018-October 2021
Figure 35: Share of Mergers and Acquisitions (by Company), January 2018-October 2021
Figure 36: Share of Other Key Developments (by Company), January 2018-October 2021
Figure 37: Market Share Analysis of Global Viral and Non-Viral Vector Manufacturing Market (by
Company), 2020
Figure 38: Growth Share Analysis for Global Viral and Non-Viral Vector Manufacturing Market (by
Company), 2020
Figure 39: Growth Share Analysis for the Global Viral and Non-Viral Vector Manufacturing Market (by
Vector Type), 2020
Figure 40: Global Viral and Non-Viral Vector Manufacturing Market Segmentation (by Vector Type)
Figure 41: Global Viral and Non-Viral Vector Manufacturing Market (by Viral and Non-Viral Vector),
$Million, 2020 and 2031
Figure 42: Global Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020-
2031
Figure 43: Global Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031
Figure 44: Global Viral and Non-Viral Vector Manufacturing Market for Adenoviral Vector $Million,
2020-2031
Figure 45: Global Viral and Non-Viral Vector Manufacturing Market for Retroviral Vector $Million, 2020-
2031
Figure 46: Global Viral and Non-Viral Vector Manufacturing Market for Adeno-Associated Viral Vector,
$Million, 2020-2031
Figure 47: Global Viral and Non-Viral Vector Manufacturing Market for Lentiviral Vector, 2020-2031
Figure 48: Global Viral and Non-Viral Vector Manufacturing Market for Vaccinia Viral Vector, $Million,
2020-2031
Figure 49: Global Viral and Non-Viral Vector Manufacturing Market for Other Viral Vector, $Million,
2020-2031
Figure 50: Global Viral and Non-Viral Vector Manufacturing Market for Non-Viral Vectors, 2020-2031
Figure 51: Global Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 52: Global Viral and Non-Viral Vector Manufacturing Market for Plasmid DNA, $Million, 2020-
2031
Figure 53: Different Types of Lipid-Based Non-Viral Vectors
Figure 54: Viral and Non-Viral Vector Manufacturing Market for Lipid-Based Non-Viral Vectors,
$Million, 2020-2031
Figure 55: Different Types of Polymers Used as Delivery Systems
Figure 56: Viral and Non-Viral Vector Manufacturing Market for Polymer-Based Non-Viral Vector,
$Million, 2020-2031
Figure 57: Viral and Non-Viral Vector Manufacturing Market for Other Non-Viral Vector, $Million, 2020-
2031
16. 15
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Figure 58: Global Viral and Non-Viral Vector Manufacturing Market Segmentation (by Disease)
Figure 59: Global Viral and Non-Viral Vector Manufacturing Market (by Disease)
Figure 60: Global Viral and Non-Viral Vector Manufacturing Market for Cancer, $Million, 2020-2031
Figure 61: List of Approved Human Gene Transfer Trials for Monogenic Disorders
Figure 62: Global Viral and Non-Viral Vector Manufacturing Market for Genetic Disease, $Million,
2020-2031
Figure 63: Global Viral and Non-Viral Vector Manufacturing Market for Infectious Disease, $Million,
2020-2031
Figure 64: Global Viral and Non-Viral Vector Manufacturing Market for Cardiovascular Disease,
$Million, 2020-2031
Figure 65: Global Viral and Non-Viral Vector Manufacturing Market for Other Diseases, 2020-2031
Figure 66: Global Viral and Non-Viral Vector Manufacturing Market Segmentation (by Application)
Figure 67: Global Viral and Non-Viral Vector Manufacturing Market (by Application), 2020 and 2031
Figure 68: Global Viral and Non-Viral Vector Manufacturing Market for Gene Therapy, $Million, 2020-
2031
Figure 69: Gene Therapy: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 70: Global Viral and Non-Viral Vector Manufacturing Market for Gene Therapy (by Viral Vector),
$Million, 2020 and 2031
Figure 71: Global Viral and Non-Viral Vector Manufacturing Market for Gene Therapy (by Non-Viral
Vector), $Million, 2020 and 2031
Figure 72: Global Viral and Non-Viral Vector Manufacturing Market for Vaccinology, $Million, 2020-
2031
Figure 73: Vaccinology: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 74: Global Viral and Non-Viral Vector Manufacturing Market for Vaccinology (by Viral Vector),
$Million, 2020 and 2031
Figure 75: Global Viral and Non-Viral Vector Manufacturing Market for Vaccinology (by Non-Viral
Vector), 2020 and 2031
Figure 76: Global Viral and Non-Viral Vector Manufacturing Market for Cell Therapy, $Million, 2020-
2031
Figure 77: Cell Therapy: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 78: Global Viral and Non-Viral Vector Manufacturing Market for Cell Therapy (by Viral Vector),
$Million, 2020 and 2031
Figure 79: Global Viral and Non-Viral Vector Manufacturing Market for Cell Therapy (by Non-Viral
Vector), $Million, 2020 and 2031
Figure 80: Global Viral and Non-Viral Vector Manufacturing Market for Other Applications, $Million,
2020-2031
Figure 81: Other Applications: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 82: Global Viral and Non-Viral Vector Manufacturing Market for Other Applications (by Viral
Vector), $Million, 2020 and 2031
Figure 83: Global Viral and Non-Viral Vector Manufacturing Market for Other Applications (by Non-Viral
Vector), $Million, 2020 and 2031
17. 16
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Figure 84: North America: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 85: U.S.: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 86: U.S.: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-
2031
Figure 87: U.S.: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and
2031
Figure 88: U.S.: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020
and 2031
Figure 89: Canada: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 90: Canada: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million,
2020-2031
Figure 91: Canada: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031
Figure 92: Canada: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 93: Europe: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 94: Germany: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 95: Germany: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million,
2020-2031
Figure 96: Germany: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031
Figure 97: Germany: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 98: U.K.: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 99: U.K.: Viral Vs Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-
2031
Figure 100: U.K.: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031
Figure 101: U.K.: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 102: France: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 103: France: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million,
2020-2031
Figure 104: France: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million,
2020 and 2031
Figure 105: France: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 106: Italy: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 107: Italy: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), 2020-2031
Figure 108: Italy: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031
18. 17
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Figure 109: Italy: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 110: Switzerland: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 111: Switzerland: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral),
$Million, 2020-2031
Figure 112: Switzerland: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million,
2020 and 2031
Figure 113: Switzerland: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector),
$Million, 2020 and 2031
Figure 114: Belgium: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 115: Belgium: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million,
2020-2031
Figure 116: Belgium: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million,
2020 and 2031
Figure 117: Belgium: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), 2020
and 2031
Figure 118: Spain: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 119: Spain: Viral and Non-Viral Vector Manufacturing Market, (Viral Vs. Non-Viral), $Million,
2020-2031
Figure 120: Spain: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031
Figure 121: Spain: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 122: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 123: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral),
$Million, 2020-2031
Figure 124: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector),
$Million, 2020 and 2031
Figure 125: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector),
$Million, 2020 and 2031
Figure 126: Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 127: China: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
Figure 128: China: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million,
2020-2031
Figure 129: China: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031
Figure 130: China: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 131: Australia: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
Figure 132: Australia: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral),
$Million, 2020-2031
19. 18
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Figure 133: Australia: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million,
2020 and 2031
Figure 134: Australia: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector),
$Million, 2020 and 2031
Figure 135: Japan: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
Figure 136: Japan: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million,
2020-2031
Figure 137: Japan: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031
Figure 138: Japan: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 139: India: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
Figure 140: India: Viral vs Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 141: India: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031
Figure 142: India: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 143: South Korea: Viral Vector and Non-Viral Vector Manufacturing Market, $Million, 2020-
2031
Figure 144: South Korea: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral),
$Million, 2020-2031
Figure 145: South Korea: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector),
$Million, 2020 and 2031
Figure 146: South Korea: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector),
$Million, 2020 and 2031
Figure 147: Singapore: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
Figure 148: Singapore: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral),
$Million, 2020-2031
Figure 149: Singapore: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million,
2020 and 2031
Figure 150: Singapore: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector),
$Million, 2020-2031
Figure 151: Rest-of-Asia-Pacific: Viral Vector and Non-Viral Vector Manufacturing Market, $Million,
2020-2031
Figure 152: Rest-of-Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-
Viral Vector), $Million, 2020-2031
Figure 153: Rest-of-Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector),
$Million, 2020 and 2031
Figure 154: Rest-of-Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral
Vector), $Million, 2020 and 2031
Figure 155: Rest-of-the-World Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
20. 19
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Figure 156: Rest-of-the-World: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-
Viral), $Million, 2020-2031
Figure 157: Rest-of-the-World: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector),
$Million, 2020 and 2031
Figure 158: Rest-of-the-World: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral
Vector), $Million, 2020 and 2031
Figure 159: Shares of Key Company Profiles
Figure 160: Boehringer Ingelheim: Service Portfolio
Figure 161: Boehringer Ingelheim: SWOT Analysis
Figure 162: Catalent, Inc.: Service/Product Portfolio
Figure 163: Catalent, Inc.: Overall Financials, $Million, 2019-2021
Figure 164: Catalent, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 165: Catalent, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 166: Catalent, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 167: Catalent, Inc.: SWOT Analysis
Figure 168: FUJIFILM Holdings Corporation: Service/Product Portfolio
Figure 169: FUJIFILM Holdings Corporation: Overall Financials, $Million, 2018-2020
Figure 170: FUJIFILM Holdings Corporation: Revenue (by Segment), $Million, 2018-2020
Figure 171: FUJIFILM Holdings Corporation: Revenue (by Region), $Million, 2018-2020
Figure 172: FUJIFILM Holdings Corporation: R&D Expenditure, $Million, 2018-2020
Figure 173: FUJIFILM Holdings Corporation: SWOT Analysis
Figure 174: Danaher Corporation: Service/Product Portfolio
Figure 175: Danaher Corporation: Overall Financials, $Million, 2018-2020
Figure 176: Danaher Corporation: Revenue (by Segment), $Million, 2018-2020
Figure 177: Danaher Corporation: Revenue (by Region), $Million, 2018-2020
Figure 178: Danaher Corporation: R&D Expenditure, $Million, 2018-2020
Figure 179: Danaher Corporation: SWOT Analysis
Figure 180: Genscript Biotech Corporation: Service/Product Portfolio
Figure 181: Genscript Biotech Corporation: Overall Financials, $Million, 2018-2020
Figure 182: Genscript Biotech Corporation: Revenue (by Segment), $Million, 2018-2020
Figure 183: Genscript Biotech Corporation: Revenue (by Region), $Million, 2018-2020
Figure 184: Genscript Biotech Corporation: R&D Expenditure, $Million, 2018-2020
Figure 185: Genscript Biotech Corporation: SWOT Analysis
Figure 186: Lonza Group AG: Service/Product Portfolio
Figure 187: Lonza Group AG: Overall Financials, $Million, 2018-2020
Figure 188: Lonza Group AG: Revenue (by Segment), $Million, 2018-2020
Figure 189: Lonza Group AG: Revenue (by Region), $Million, 2018-2020
Figure 190: Lonza Group AG: R&D Expenditure, $Million, 2018-2020
Figure 191: Lonza Group AG: SWOT Analysis
21. 20
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Figure 192: Merck KGaA Inc.: Service/Product Portfolio
Figure 193: Merck KGaA Inc.: Overall Financials, $Million, 2018-2020
Figure 194: Merck KGaA Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 195: Merck KGaA Inc.: Revenue (by Region), $Million, 2018-2020
Figure 196: Merck KGaA Inc.: R&D Expenditure, $Million, 2018-2020
Figure 197: Merck KGaA Inc.: SWOT Analysis
Figure 198: Oxford Biomedica plc: Service/Product Portfolio
Figure 199: Oxford Biomedica plc: Overall Financials, $Million, 2018-2020
Figure 200: Oxford Biomedica plc: Revenue (by Segment), $Million, 2018-2020
Figure 201: Oxford Biomedica plc: Revenue (by Region), $Million, 2018-2020
Figure 202: Oxford Biomedica plc: R&D Expenditure, $Million, 2018-2020
Figure 203: Oxford Biomedica plc: SWOT Analysis
Figure 204: Sartorius AG: Service/Product Portfolio
Figure 205: Sartorius AG: Overall Financials, $Million, 2018-2020
Figure 206: Sartorius AG: Revenue (by Segment), $Million, 2018-2020
Figure 207: Sartorius AG: Revenue (by Region), $Million, 2018-2020
Figure 208: Sartorius AG: R&D Expenditure, $Million, 2018-2020
Figure 209: Sartorius AG: SWOT Analysis
Figure 210: Takara Bio Inc.: Service/Product Portfolio
Figure 211: Takara Bio Inc.: Overall Financials, $Million, 2018-2020
Figure 212: Takara Bio Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 213: Takara Bio Inc.: Revenue (by Region), $Million, 2018-2020
Figure 214: Takara Bio Inc.: R&D Expenditure, $Million, 2018-2020
Figure 215: Takara Bio Inc.: SWOT Analysis
Figure 216: Thermo Fisher Scientific, Inc.: Service/Product Portfolio
Figure 217: Thermo Fisher Scientific, Inc.: Overall Financials, $Million, 2018-2020
Figure 218: Thermo Fisher Scientific, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 219: Thermo Fisher Scientific, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 220: Thermo Fisher Scientific, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 221: Thermo Fisher Scientific, Inc.: SWOT Analysis
Figure 222: Wuxi AppTec: Service/Product Portfolio
Figure 223: Wuxi AppTec: Overall Financials, $Million, 2018-2020
Figure 224: Wuxi AppTec: Revenue (by Segment), $Million, 2018-2020
Figure 225: Wuxi AppTec: Revenue (by Region), $Million, 2018-2020
Figure 226: Wuxi AppTec: R&D Expenditure, $Million, 2018-2020
Figure 227: Wuxi AppTec: SWOT Analysis
Figure 228: Acuitas Therapeutics: Service/Product Portfolio
Figure 229: Acuitas Therapeutics: SWOT Analysis
Figure 230: Evonik Industries AG: Service/Product Portfolio
22. 21
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Figure 231: Evonik Industries AG: Overall Financials, $Million, 2018-2020
Figure 232: Evonik Industries AG: Revenue (by Segment), $Million, 2018-2020
Figure 233: Evonik Industries AG: Revenue (by Region), $Million, 2018-2020
Figure 234: Evonik Industries AG: R&D Expenditure, $Million, 2018-2020
Figure 235: Evonik Industries AG: SWOT Analysis
Figure 236: Exelead, Inc.: Service/Product Portfolio
Figure 237: Exelead, Inc.: SWOT Analysis
Figure 238: Entos Pharmaceuticals: Service/Product Portfolio
Figure 239: Entos Pharmaceuticals: SWOT Analysis
Figure 240: Genevant Sciences GmbH: Service/Product Portfolio
Figure 241: Genevant Sciences GmbH: SWOT Analysis
Figure 242: T&T Scientific Corporation: Service/Product Portfolio
Figure 243: T&T Scientific Corporation: SWOT Analysis
Figure 244: Moderna, Inc.: Service/Product Portfolio
Figure 245: Moderna, Inc.: Overall Financials, $Million, 2018-2020
Figure 246: Moderna, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 247: Moderna, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 248: Moderna, Inc.: SWOT Analysis
Figure 249: CureVac N.V.: Product Portfolio
Figure 250: CureVac N.V.: Overall Financials, $Million, 2018-2020
Figure 251: CureVac N.V.: Revenue (by Region), $Million, 2018-2020
Figure 252: CureVac N.V.: R&D Expenditure, $Million, 2018-2020
Figure 253: CureVac N.V.: SWOT Analysis
23. 22
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
List of Tables
Table 1: Leading Segments of the Global Viral and Non-Viral Vector Manufacturing Market, 2020
and 2031
Table 2: Advantages and Disadvantages of Viral Vectors
Table 3: Advantages and Disadvantages of Non-Viral Vectors
Table 4: COVID-19 Candidate Viral Vector Vaccines in Clinical Stage (as of 31st July 2020)
Table 5: COVID-19 Candidate Viral Vector Vaccines in Preclinical Stage (as of 31 July 2020)
Table 6: Recent Approvals for Gene Therapy
Table 7: Companies Offering Gene Therapies and Their Cost
Table 8: Global Regulatory Scenario
Table 9: Patents Related to Viral Vectors (January 2018-February 2021)
Table 10: Patents Related to Non-Viral Vectors (January 2018-February 2021)
Table 11: Examples of Viral Vectors Used in Gene Therapy
Table 12: List of Non-Viral Vector-Based Vaccines against Infectious Diseases
Table 13: Features of Vectors Used in Cardiovascular Therapy
Table 14: Examples of Clinical Trials Using Viral Vectors
Table 15: List of Clinical Trials Using Non-Viral Vectors
Table 16: Advantages and Disadvantages Associated with Major Viral Vectors
24. 23
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s
digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions
worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other
innovative solutions.
Know More Know More
Know More
Know More
25. 24
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to
orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth.
This document and its contents are confidential and may not be further distributed, published or reproduced,
in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS
Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly
through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information
to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce
Information in legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information is
available. Any recommendation contained in this report may not be suitable for all investors or businesses.
The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to
market fluctuations and business, economic and competitive uncertainties and contingencies
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135
26. 25
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
BIS RESEARCH INC.
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
www.bisresearch.com